mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)

Hasmukh Prajapati, J. R. Spivey, S. I. Hanish, B. F. El-rayes, J. S. Kauh, Z. Chen, H. S. Kim

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Background: We analyzed the magnetic resonance imaging (MRI) responses by world health organization (WHO), response evaluation criteria in solid tumor (RECIST), European Association for the Study of Liver (EASL), and modified RECIST (mRECIST) guidelines and correlated with survival after doxorubicin (Adriamycin; Pharmacia & Upjohn, Peapac, NJ). drug-eluting beads transarterial chemoembolization (DEB TACE) in patients with unresectable hepatocellular carcinoma (HCC). Patients and methods: The early target and overall imaging responses were studied in 120 consecutive patients treated with DEB TACE for unresectable HCC, using RECIST, WHO, EASL, and mRECIST guidelines on contrast-enhanced dynamic liver MRI. The median period between the DEB TACE and assessment scan was 33.50 days. Survival analyses were carried out with the Kaplan-Meier method and the Cox proportional model. Results: WHO and RECIST1.1 had poor correlation with survival. mRECIST and EASL had significant correlation with survival with target lesion response rates of 63.3 and 48.3 and with overall response rates of 52.5 and 39.2, respectively. The responders of EASL and mRECIST had significant median survival (P ≤ 0.0001). Moreover, mRECIST was better than EASL in predicting survival, because the survival difference between responders and non-responders of overall response was statistically significant (P 0.013) for mRECIST, but not for EASL (P 0.064). Conclusions: EASL and mRECIST responses measured on MRI at an early time point after DEB TACE predicted survival. mRECIST response demonstrated higher survival correlation than EASL.

Original languageEnglish (US)
Article numbermds605
Pages (from-to)965-973
Number of pages9
JournalAnnals of Oncology
Volume24
Issue number4
DOIs
StatePublished - Apr 1 2013

Fingerprint

Doxorubicin
Hepatocellular Carcinoma
Magnetic Resonance Imaging
Survival
Liver
Pharmaceutical Preparations
Response Evaluation Criteria in Solid Tumors
Guidelines
Survival Analysis
Proportional Hazards Models

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). / Prajapati, Hasmukh; Spivey, J. R.; Hanish, S. I.; El-rayes, B. F.; Kauh, J. S.; Chen, Z.; Kim, H. S.

In: Annals of Oncology, Vol. 24, No. 4, mds605, 01.04.2013, p. 965-973.

Research output: Contribution to journalArticle

@article{4c61792c8c6949fd9d69d805115815b1,
title = "mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)",
abstract = "Background: We analyzed the magnetic resonance imaging (MRI) responses by world health organization (WHO), response evaluation criteria in solid tumor (RECIST), European Association for the Study of Liver (EASL), and modified RECIST (mRECIST) guidelines and correlated with survival after doxorubicin (Adriamycin; Pharmacia & Upjohn, Peapac, NJ). drug-eluting beads transarterial chemoembolization (DEB TACE) in patients with unresectable hepatocellular carcinoma (HCC). Patients and methods: The early target and overall imaging responses were studied in 120 consecutive patients treated with DEB TACE for unresectable HCC, using RECIST, WHO, EASL, and mRECIST guidelines on contrast-enhanced dynamic liver MRI. The median period between the DEB TACE and assessment scan was 33.50 days. Survival analyses were carried out with the Kaplan-Meier method and the Cox proportional model. Results: WHO and RECIST1.1 had poor correlation with survival. mRECIST and EASL had significant correlation with survival with target lesion response rates of 63.3 and 48.3 and with overall response rates of 52.5 and 39.2, respectively. The responders of EASL and mRECIST had significant median survival (P ≤ 0.0001). Moreover, mRECIST was better than EASL in predicting survival, because the survival difference between responders and non-responders of overall response was statistically significant (P 0.013) for mRECIST, but not for EASL (P 0.064). Conclusions: EASL and mRECIST responses measured on MRI at an early time point after DEB TACE predicted survival. mRECIST response demonstrated higher survival correlation than EASL.",
author = "Hasmukh Prajapati and Spivey, {J. R.} and Hanish, {S. I.} and El-rayes, {B. F.} and Kauh, {J. S.} and Z. Chen and Kim, {H. S.}",
year = "2013",
month = "4",
day = "1",
doi = "10.1093/annonc/mds605",
language = "English (US)",
volume = "24",
pages = "965--973",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)

AU - Prajapati, Hasmukh

AU - Spivey, J. R.

AU - Hanish, S. I.

AU - El-rayes, B. F.

AU - Kauh, J. S.

AU - Chen, Z.

AU - Kim, H. S.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Background: We analyzed the magnetic resonance imaging (MRI) responses by world health organization (WHO), response evaluation criteria in solid tumor (RECIST), European Association for the Study of Liver (EASL), and modified RECIST (mRECIST) guidelines and correlated with survival after doxorubicin (Adriamycin; Pharmacia & Upjohn, Peapac, NJ). drug-eluting beads transarterial chemoembolization (DEB TACE) in patients with unresectable hepatocellular carcinoma (HCC). Patients and methods: The early target and overall imaging responses were studied in 120 consecutive patients treated with DEB TACE for unresectable HCC, using RECIST, WHO, EASL, and mRECIST guidelines on contrast-enhanced dynamic liver MRI. The median period between the DEB TACE and assessment scan was 33.50 days. Survival analyses were carried out with the Kaplan-Meier method and the Cox proportional model. Results: WHO and RECIST1.1 had poor correlation with survival. mRECIST and EASL had significant correlation with survival with target lesion response rates of 63.3 and 48.3 and with overall response rates of 52.5 and 39.2, respectively. The responders of EASL and mRECIST had significant median survival (P ≤ 0.0001). Moreover, mRECIST was better than EASL in predicting survival, because the survival difference between responders and non-responders of overall response was statistically significant (P 0.013) for mRECIST, but not for EASL (P 0.064). Conclusions: EASL and mRECIST responses measured on MRI at an early time point after DEB TACE predicted survival. mRECIST response demonstrated higher survival correlation than EASL.

AB - Background: We analyzed the magnetic resonance imaging (MRI) responses by world health organization (WHO), response evaluation criteria in solid tumor (RECIST), European Association for the Study of Liver (EASL), and modified RECIST (mRECIST) guidelines and correlated with survival after doxorubicin (Adriamycin; Pharmacia & Upjohn, Peapac, NJ). drug-eluting beads transarterial chemoembolization (DEB TACE) in patients with unresectable hepatocellular carcinoma (HCC). Patients and methods: The early target and overall imaging responses were studied in 120 consecutive patients treated with DEB TACE for unresectable HCC, using RECIST, WHO, EASL, and mRECIST guidelines on contrast-enhanced dynamic liver MRI. The median period between the DEB TACE and assessment scan was 33.50 days. Survival analyses were carried out with the Kaplan-Meier method and the Cox proportional model. Results: WHO and RECIST1.1 had poor correlation with survival. mRECIST and EASL had significant correlation with survival with target lesion response rates of 63.3 and 48.3 and with overall response rates of 52.5 and 39.2, respectively. The responders of EASL and mRECIST had significant median survival (P ≤ 0.0001). Moreover, mRECIST was better than EASL in predicting survival, because the survival difference between responders and non-responders of overall response was statistically significant (P 0.013) for mRECIST, but not for EASL (P 0.064). Conclusions: EASL and mRECIST responses measured on MRI at an early time point after DEB TACE predicted survival. mRECIST response demonstrated higher survival correlation than EASL.

UR - http://www.scopus.com/inward/record.url?scp=84875601700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875601700&partnerID=8YFLogxK

U2 - 10.1093/annonc/mds605

DO - 10.1093/annonc/mds605

M3 - Article

VL - 24

SP - 965

EP - 973

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

M1 - mds605

ER -